Identifying Disparities in Type 2 Diabetes Among Asian Americans: The Pan Asian C

确定亚裔美国人 2 型糖尿病的差异：泛亚裔 C

• 批准号: 7837912
• 负责人: Latha P Palaniappan
• 金额: $ 55.79万
• 依托单位: PALO ALTO MEDICAL FOUNDATION RES INST
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-25 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7837912
• 关键词: 2,4-thiazolidinedione; Address; Adult; Advocate; Affect; Age; Asian Americans; Asian Indian; Asians; Body Weight; Body Weight decreased; Body mass index; California; Caring; Chinese People; Chronic Disease; Clinical; Clinical effectiveness; Cohort Studies; Complications of Diabetes Mellitus; Data; Databases; Diabetes Mellitus; Diabetic Nephropathy; Diabetic Retinopathy; Effectiveness; Electronic Health Record; Ethnic Origin; Ethnic group; Filipino; Funding; Gender; Genetic; Goals; Healthcare Systems; Hemoglobin; High Density Lipoprotein Cholesterol; High Prevalence; Human Resources; Impact evaluation; Insulin Resistance; Insurance Coverage; Japanese Population; Knowledge; Koreans; Life; Link; Metabolic; Metformin; Minority Groups; Morbidity - disease rate; Myocardial Infarction; NIH Program Announcements; Non-Insulin-Dependent Diabetes Mellitus; Not Hispanic or Latino; Obesity; Oral; Pan Genus; Patients; Pharmaceutical Preparations; Pharmacists; Pharmacotherapy; Physicians; Population; Public Health; Race; Recovery; Research; Risk; Risk Factors; Role; Sampling; Stroke; Subgroup; Thiazolidinediones; Triglycerides; United States; United States National Institutes of Health; clinical care; cohort; comparative; comparative effectiveness; compare effectiveness; cost; cost effectiveness; diabetic; follow-up; health disparity; improved; parent grant; preference; prospective; public health relevance; response; treatment response

DESCRIPTION (provided by applicant): The revision to the parent grant, 5 R01 DK081371-02: "Identifying Disparities in Type 2 Diabetes Among Asian Americans: The Pan Asian Cohort Study," is in response to NOT-OD-09-058: "NIH Announces the Availability of Recovery Act Funds for Competitive Revision Applications." The parent grant is funded from January 15, 2009 - December 31, 2013 in response to Program Announcement PA-07-388: "Identifying and Reducing Diabetes and Obesity Related Health Disparities within Healthcare Systems (R01)." This five-year study addresses the lack of knowledge regarding type 2 diabetes and obesity in Asian Americans, both as an aggregate group and as distinct subgroups. Relatively little is known about how Asian subgroups differ in type 2 diabetes riskfactors and complications when compared to the Non-Hispanic White population, for which numerous study findings have informed both practice of care and public health efforts in the United States. The parent grant utilizes a mixed historical and prospective longitudinal cohort to address these research questions of significant public health import, linking existing clinical databases to construct a large (140,000 Asian adults) cohort of a multiethnic sample of contemporary Asians in California. The revision, a two-year study, aims to additionally compare the effectiveness of oral drugs for treatment of type 2 diabetes among Asian subgroups in the same electronically linked cohort. It is well-known that type 2 diabetes manifests differently in race/ethnic groups, and that race/ethnic groups respond differently to the same pharmacotherapy. Treatment options for type 2 diabetes are numerous, and previous studies have demonstrated differences in metabolic responses to certain oral drugs according to race/ethnicity. This creates a need for more race/ethnic specific data comparing the effects of medication use to be able to improve diabetes care in Asian Americans in the United States. The wealth of real-life data captured within the clinical cohort will be utilized to compare the effectiveness of oral drugs to treat type 2 diabetes among Asian subgroups and to study existing preferences for certain drugs among patients and physicians. Predictors of initial choice of oral drug (in physicians and patients), intermediate and long-term effectiveness of existing oral drugs on type 2 diabetes and its complications, and the cost-effectiveness of these therapies will be investigated under this competitive revision. This revision will contribute valuable knowledge for physicians, patients, and public health advocates on the clinical and cost effectiveness of various oral type 2diabetes therapies in Asian Americans. PUBLIC HEALTH RELEVANCE: Asian Americans (Asian Indian, Chinese, Filipino, Japanese, Korean, and Vietnamese) are disproportionately affected by type 2 diabetes. There is no data on comparative effectiveness of oral drugs to treat type 2 diabetes in Asian American subgroups. Our study will address this gap in knowledge.

描述（由申请人提供）：对父母赠款的修订，5 R01 DK081371-02：“识别亚裔美国人中2型糖尿病的差异：PAN AIS COHORT研究，“ PAN ASIAN COHORT研究”是对NOT-OD-09-058的响应：“ NIH宣布恢复ACT ACT对有能力的振兴的可用性。”父母赠款是从2009年1月15日至2013年12月31日的资金，以应对计划公告PA-07-388：“识别和减少医疗保健系统（R01）内的糖尿病和肥胖相关的糖尿病和肥胖相关的差异。”这项为期五年的研究涉及亚裔美国人的2型糖尿病和肥胖症的知识，无论是作为一个群体还是作为不同的亚组。与非西班牙裔白人人口相比，亚洲亚组在2型糖尿病风险型和并发症方面的差异相对鲜为人知，为此，许多研究结果都为美国的护理和公共卫生努力提供了信息。父母的赠款利用混合的历史和前瞻性纵向队列来解决这些重大公共卫生进口的研究问题，并将现有的临床数据库联系起来，以构建加利福尼亚州当代亚洲人的多民族样本。修订是一项为期两年的研究，旨在额外比较口服药物在同一电子连接的同时亚洲亚组中治疗2型糖尿病的有效性。众所周知，2型糖尿病在种族/族裔群体中表现出不同的表现，种族/族裔群体对同一药物治疗的反应也有所不同。 2型糖尿病的治疗选择很多，并且先前的研究表明，根据种族/种族，对某些口服药物的代谢反应差异。这需要比较更多的种族/种族特定数据，以比较药物使用的影响以改善美国亚裔美国人的糖尿病护理。将利用临床队列中捕获的现实生活数据的财富来比较口服药物在亚洲亚组中治疗2型糖尿病的有效性，并研究患者和医生中某些药物的现有偏好。预测口服药物的初步选择（在医师和患者中），现有口服药物对2型糖尿病及其并发症的中间和长期有效性以及这些疗法的成本效益将在此竞争性修订下进行研究。这项修订将为医师，患者和公共卫生倡导者提供宝贵的知识，以了解亚裔美国人各种口服2糖尿病疗法的临床和成本效益。 公共卫生相关性：亚裔美国人（亚洲印第安人，中国，菲律宾，日本，韩裔和越南人）受2型糖尿病的影响不成比例。没有关于口服药物在亚裔美国亚裔亚组中治疗2型糖尿病的比较有效性的数据。我们的研究将解决这一知识的差距。